CD73 Biomarker Monitoring Disease Severity and Treatment Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable biomarker for monitoring disease development and assessing the efficacy of therapies, particularly for cytokine and statin treatments, which often show variable responses in patients.
Innovation Solution
Measuring soluble CD73 activity in tissue fluids as a biomarker to monitor disease severity and treatment response, using techniques such as immunodetection and thin layer chromatography to quantify CD73 protein or activity levels over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytokine therapy (interferon alpha or beta) is used to treat diseases, then therapeutic benefit is achieved in some patients, but treatment response is variable and many patients become refractory over time
Solution Approach 1:
The patent applies preliminary action by measuring CD73 levels before initiating cytokine therapy to predict which patients will respond to treatment. This allows clinicians to select the most appropriate patients for interferon therapy in advance, avoiding treatment in patients unlikely to benefit and thereby improving overall treatment response consistency across the patient population.
Solution Approach 2:
The patent implements feedback by repeatedly measuring CD73 levels during therapy to monitor treatment response in real-time. When CD73 levels fail to increase or decrease (depending on the disease context), it indicates treatment refractoriness, allowing clinicians to adjust or discontinue therapy before complete treatment failure occurs, thus maintaining reliable and adaptable treatment outcomes.
2Measurement precision
If repeated CD73 measurements are performed to monitor disease progression and treatment response, then accurate assessment of therapy efficacy is achieved, but increased measurement frequency and complexity are required
Solution Approach 1:
The patent applies self-service by utilizing CD73 as a self-indicating biomarker that naturally reflects disease state and treatment response without requiring complex external assays. CD73 levels directly correlate with disease activity and therapeutic effect, allowing the biological system itself to provide the measurement signal, thereby simplifying the monitoring process while maintaining high measurement precision.
Solution Approach 2:
The patent employs parameter changes by measuring CD73 concentration or activity levels as a quantitative parameter that changes in response to disease progression and treatment. This single parameter provides comprehensive information about both disease state and therapeutic efficacy, reducing the need for multiple complex measurements while maintaining high monitoring accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides valuable information on disease progression or treatment effectiveness by correlating altered CD73 levels with disease activity and treatment outcomes, enabling more informed therapeutic decisions.
Implementation Method 1
CD73 is a cell-surface enzyme that has 5'-ectonucleotidase activity. It thus mediates the conversion of monophosphorylated purine nucleotides into corresponding nucleosides. For example, dephosphorylation of AMP to adenosine is catalyzed by CD73.
Implementation Method 2
Measuring soluble CD73 activity in tissue fluids as a biomarker to monitor disease severity and treatment response, using techniques such as immunodetection and thin layer chromatography to quantify CD73 protein or activity levels over time.
Implementation Method 3
using techniques such as immunodetection and thin layer chromatography to quantify CD73 protein or activity levels over time.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.